BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35491791)

  • 1. Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer's Disease.
    Leng F; Zhan Z; Sun Y; Liu F; Edison P; Sun Y; Wang Z;
    J Alzheimers Dis; 2022; 88(1):117-126. PubMed ID: 35491791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
    Li TR; Lyu DY; Liu FQ;
    J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.
    Falcon C; Monté-Rubio GC; Grau-Rivera O; Suárez-Calvet M; Sánchez-Valle R; Rami L; Bosch B; Haass C; Gispert JD; Molinuevo JL
    Neuroimage Clin; 2019; 23():101801. PubMed ID: 30978656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
    Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
    Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
    Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
    J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer's disease.
    Hok-A-Hin YS; Del Campo M; Boiten WA; Stoops E; Vanhooren M; Lemstra AW; van der Flier WM; Teunissen CE
    J Neuroinflammation; 2023 May; 20(1):107. PubMed ID: 37147668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease.
    Gispert JD; Suárez-Calvet M; Monté GC; Tucholka A; Falcon C; Rojas S; Rami L; Sánchez-Valle R; Lladó A; Kleinberger G; Haass C; Molinuevo JL
    Alzheimers Dement; 2016 Dec; 12(12):1259-1272. PubMed ID: 27423963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.
    Franzmeier N; Suárez-Calvet M; Frontzkowski L; Moore A; Hohman TJ; Morenas-Rodriguez E; Nuscher B; Shaw L; Trojanowski JQ; Dichgans M; Kleinberger G; Haass C; Ewers M;
    Mol Neurodegener; 2020 Oct; 15(1):57. PubMed ID: 33032659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
    Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
    Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification.
    Knapskog AB; Henjum K; Idland AV; Eldholm RS; Persson K; Saltvedt I; Watne LO; Engedal K; Nilsson LNG
    Sci Rep; 2020 Sep; 10(1):15886. PubMed ID: 32985583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
    Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
    Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.
    Ewers M; Franzmeier N; Suárez-Calvet M; Morenas-Rodriguez E; Caballero MAA; Kleinberger G; Piccio L; Cruchaga C; Deming Y; Dichgans M; Trojanowski JQ; Shaw LM; Weiner MW; Haass C;
    Sci Transl Med; 2019 Aug; 11(507):. PubMed ID: 31462511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
    Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
    Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.
    Park SH; Lee EH; Kim HJ; Jo S; Lee S; Seo SW; Park HH; Koh SH; Lee JH
    Sci Rep; 2021 Jun; 11(1):13050. PubMed ID: 34158530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.